PYC Therapeutics Limited, often referred to as PYC, is an innovative biotechnology company headquartered in Australia. Founded in 2017, PYC focuses on developing transformative RNA-targeted therapies for genetic disorders, positioning itself at the forefront of the biotechnology industry. With a commitment to addressing unmet medical needs, PYC Therapeutics has made significant strides in its research and development efforts, particularly in the field of RNA therapeutics. The company’s core products, which include proprietary RNA-targeted drug candidates, are designed to offer unique solutions for conditions caused by genetic mutations. PYC's dedication to advancing therapeutic options has garnered recognition within the industry, establishing it as a notable player in the biotechnology landscape. As it continues to expand its operational reach, PYC Therapeutics remains committed to innovation and improving patient outcomes globally.
How does PYC Therapeutics Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
PYC Therapeutics Limited's score of 14 is lower than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
PYC Therapeutics Limited, headquartered in Australia, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of emissions data and climate commitments suggests that PYC Therapeutics may still be in the early stages of developing a comprehensive sustainability strategy. As the industry increasingly prioritises climate action, it will be essential for PYC Therapeutics to establish measurable targets and initiatives to align with global climate goals.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
PYC Therapeutics Limited has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
